Piramal Pharma Solutions entered into a manufacturing agreement with Botanix SB Inc. The deal supports the development and commercial supply of Sofdra. This product is the first FDA-approved new chemical entity for primary axillary hyperhidrosis. Botanix SB Inc. operates as a subsidiary of Botanix Pharmaceuticals Limited.
Piramal Pharma Solutions is a contract development and manufacturing organization. The company provides drug substance development services across the drug life cycle. It will use its North American drug substance facilities for this project. The collaboration ensures consistent patient access to the breakthrough therapy.
Advanced Twin-Site Manufacturing Capabilities
The company will start validation services for Sofpironium Bromide. This chemical serves as the active pharmaceutical ingredient in Sofdra. The initial manufacturing work takes place at the Riverview, Michigan facility.
The company will later consider validating the process at its Aurora, Canada facility. This choice requires successful regulatory approval at the Michigan site. This twin-site strategy gives Botanix options for a dual-source commercial supplier. It enhances long-term supply chain flexibility and security.
The two facilities have deep proficiency in drug substance development. Their experience spans from research and development through commercialization. Recent investments added advanced equipment and unified systems to these locations.
“This business partnership demonstrates our ability to deliver tailored, resilient solutions for organizations like Botanix,” said Peter DeYoung, CEO, Piramal Global Pharma. “Our North American drug substance facilities are equipped with the expertise, advanced technology, and cutting-edge capabilities required to help derisk the Sofdra supply chain and ensure this breakthrough therapy reaches patients in need with consistency and efficiency.”
The dual sites provide validation options that offer excellent redundancy. This setup gives partners continuous supply chains and scheduling flexibility. Production can shift seamlessly between facilities if geopolitical issues arise. This keeps the supply steady for patients worldwide.
The twin-site strategy also delivers clear financial benefits. It helps partners balance quality and time effectively. Derisking the supply chain reduces the cost of goods sold for Botanix.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: PRNewswire.com
